Previous Close | 4.9200 |
Open | 4.9400 |
Bid | 4.2500 x 800 |
Ask | 7.8800 x 800 |
Day's Range | 4.8500 - 5.1300 |
52 Week Range | 3.9600 - 35.4050 |
Volume | |
Avg. Volume | 419,031 |
Market Cap | 282.586M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines Cash balance of $337.0M expected to fund operations into 2024 CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and first quarter 2022 financial results. “We are making s
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11th at 11:00 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s web
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene Therapy panel discussion at the 42nd Annual Cowen Health Care Conference on Wednesday, March 9 at 12:50 p.m. ET. A live webcast of the panel will be available on the investor section of the company’s w